Hepatocellular carcinoma Sorafenib is indicated for the treatment of hepatocellular carcinoma (see section 5.1). Renal cell carcinoma Sorafenib is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.
Hepatocellular carcinoma Sorafenib Zentiva is indicated for the treatment of hepatocellular carcinoma (see section 5.1). Renal cell carcinoma Sorafenib Zentiva is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.
The 2018 ESMO Clinical Practice Guidelines on hepatocellular carcinoma (HCC) are conceived to provide the standard approach to diagnosis and local and systemic treatment of HCC.